Navigation Links
BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
Date:5/28/2008

- Strategic Collaboration with the Gynecologic Oncology Group -

BRISBANE, Calif., May 28 /PRNewswire/ -- BiPar Sciences, Inc. today announced it has expanded its clinical trials program through the initiation of an additional Phase 2 study of its lead product candidate BSI-201. The trial will assess BSI-201, the first ADP-ribose polymerase (PARP) inhibitor in the company's DNA repair portfolio, for the treatment of uterine carcinosarcoma or malignant mixed mullerian tumors.

This multi-center, open-label, single-arm study in patients with recurrent or advanced uterine carcinosarcomas will evaluate BSI-201 in combination with standard treatment and is being conducted by the Gynecologic Oncology Group, a National Cancer Institute-funded research organization which focuses on gynecologic malignancies. The primary objective of this trial is to determine the antitumor activity of BSI-201 plus carboplatin/paclitaxel in patients with recurrent or advanced uterine carcinosarcomas.

The identification of mixed mullerian tumors of the uterus as a target for its PARP inhibitor was the result of BiPar's ground-breaking work that assessed PARP1 gene expression across all types of human cancers. Striking up- regulation of the PARP gene was a characteristic of cancer of female reproductive organs -- breast, ovary and uterus. PARP over-expression was particularly intense in uterine mixed mullerian tumors, a cancer for which there is no well established standard, effective treatment. BSI-201 blocks a pathway by which tumor cells resist the effects of DNA damaging chemotherapy. Therefore BSI-201 may work to potentiate the effects of current therapies for uterine cancer.

"Current treatments for uterine carcinosarcoma remain limited and are often poorly tolerated," said Carol Aghajanian, M.D., chief of the gynecologic medical oncology service at Memorial Sloan-Kettering Cancer Center and the Study Chair for this Gynecologic Oncology Group investigation. "The combination of a PARP inhibitor such as BSI-201 which specifically targets uterine tumors in a unique way may boost the effects of common chemotherapy regimen. We hope this drug will play a transformative role in the way we approach treatment."

Uterine cancer is the most common gynecological tumor, and the fourth most-common type of tumor in women. Forty thousand new diagnoses are made each year in the United States.

"Because PARP is expressed at high levels in uterine cancer and particularly MMT, we believe that BSI-201 has the potential to selectively target these highly aggressive and poorly treated tumors," said BiPar Executive Vice President Barry Sherman, M.D. "This will be our third study designed around our gene expression data, which has been invaluable in selecting types of cancer that will most likely respond to PARP inhibition."

About BiPar Sciences

BiPar Sciences is a drug development company with a therapeutic focus on exploring novel mechanisms of action in oncology. The lead development program is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. The lead product within that program is BSI-201, a platform drug with the potential to be a superior new treatment across a range of tumor types, both as monotherapy and in combination with chemotherapy. The company is currently testing BSI-201 in a range of Phase 2 trials in breast, brain, uterine and ovarian cancer.


'/>"/>
SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
2. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
3. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
4. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
5. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
6. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
7. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
8. Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... 2017  South Korean-based healthcare product Development Company I.M. ... on Kickstarter. The device will educate the user about ... better efficiency compared to the dated and pricey CPR ... efficacy of the compression for a more informed CPR ... to raise $5,000. ...
(Date:10/2/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... , and named its founder as Diplomat,s chief information ... Tennessee , will operate under Diplomat subsidiary Envoy ... for health care partners to include IT outsourcing, consulting, ... "In an interoperable world, technology delivers comprehensive insight and ...
(Date:10/2/2017)... 2, 2017 Halo Labs announces the European launch of ... the HORIZON at MIBio 2017 in Cambridge, U.K ... particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity while ... technique Backgrounded Membrane Imaging. ... HORIZON subvisible particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association ... standards of excellence for the field of eating disorders, announces the opening of ... 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes ... of the facility as part of a disaster drill on October 3rd. , Apple ... Shelton City Emergency Manager, as well as the Connecticut Long Term Care Mutual ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... ... Planet Fitness, one of the largest and fastest growing franchisors and operators ... location in Covington, LA at 401 N. U.S. Highway 190, in January of 2018. ... in the Holiday Square shopping center. Its location allows it to serve both Covington ...
Breaking Medicine News(10 mins):